Clinical Trial

Efficacy and Safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 17, 2025 (before its estimated March 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the efficacy and safety of Chemotherapy With XELOX (Oxaliplatin + Capecitabine) and Bevacizumab in Combination With Adebrelimab in First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-02-21.
Trial Details
NCT Number NCT06282445
Lead Sponsor The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Conditions Colorectal Cancer Metastatic
Enrollment 36 participants
Start Date 2024-03-01
Primary Completion 2025-03-01 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-17